Featured Research

from universities, journals, and other organizations

Researchers Develop First Oral Drug To Treat Smallpox Infection

Date:
March 20, 2002
Source:
Department Of Veterans Affairs
Summary:
An oral drug that halts the deadly action of smallpox and related orthopox viruses in lab tissue culture cells and in cowpox-infected mice has been developed by researchers at the Veterans Affairs San Diego Healthcare System (VASDHS) and the University of California, San Diego (UCSD) School of Medicine, and is being evaluated by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

March 20, 2002 – An oral drug that halts the deadly action of smallpox and related orthopox viruses in lab tissue culture cells and in cowpox-infected mice has been developed by researchers at the Veterans Affairs San Diego Healthcare System (VASDHS) and the University of California, San Diego (UCSD) School of Medicine, and is being evaluated by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

Called hexadecyloxypropyl-cidofovir (HDP-CDV), the antiviral drug blocks the activity of variola, the virus that causes smallpox and orthopox viruses, halting their ability to replicate and spread.

Developed as part of a national research effort to design antiviral drugs for people infected by smallpox, HDP-CDV is not yet available for human use. The drug must still undergo additional testing in animals and safety trials in healthy people.

Announced today at the 15th International Conference on Antiviral Research in Prague, Czech Republic, HDP-CDV is a potent derivative of an existing compound, cidofovir, which inhibits smallpox virus replication. However, cidofovir must be administered intravenously, thus limiting its fast application in the event of a bioterrorism attack or widespread epidemic.

Found to be 100 times more potent then cidofovir, which is not readily taken up by cells, HDP-CDV is a modified cidofovir that exploits the cell’s own machinery to get in more effectively. HDP-CDV was developed by Karl Y. Hostetler, M.D., director, Endocrine and Metabolism Clinic, Veterans Affairs San Diego Healthcare System and UCSD professor of medicine, and James Beadle, Ph.D., VASDHS and UCSD research professor, who presented their results at the international conference.

The VASDHS/UCSD work was done in collaboration with research groups headed by John Huggins, Ph.D., USAMRIID, Fort Detrick, Maryland and Earl Kern, Ph.D., University of Alabama, Birmingham.

The effort was initiated in 1999 when the National Institute of Allergy and Infectious Diseases (NIAID) asked the VASDHS/UCSD team to develop an oral version of cidofovir.

NIAID, USAMRIID and the Centers for Disease Control and Prevention (CDC) in Atlanta, oversee most of the country’s effort to develop antiviral therapies for smallpox. After screening hundreds of existing compounds for activity against smallpox while working in the CDC’s Biosafety Level 4 (maximum containment) Laboratory in Atlanta, USAMRIID identified cidofovir as active against smallpox. The drug is currently used to treat retinal infections caused by cytomegalovirus.

"Cidofovir’s drawback is poor oral bioavailability. It can only be given intravenously," Hostetler said. "If you’ve got thousands of people exposed to smallpox, a drug that needs to be injected would be difficult to use widely."

If continuing studies support HDP-CDV’s effectiveness and safety, the drug could be given in pill or capsule form over 5 to 14 days for the prevention and treatment of smallpox in persons exposed to the disease, Hostetler said.

The Huggins group from USAMRIID announced at the 15th International Conference on Antiviral Research that HDP-CDV was effective in blocking the replication of several strains of smallpox in tissue culture. Surprisingly, the HDP-CDV compound was 100 times more active than cidofovir in slowing smallpox reproduction.

Also presented at the conference were Huggins’ results of HDP-CDV therapy in mice infected with cowpox, a poxvirus closely related to smallpox. Working in collaboration with Hostetler’s group, Huggins and coworkers at USAMRIID found that 5 daily oral doses of HDP-CDV given after infection prevented death from cowpox infection.

The Huggins group also found that virus levels in the lungs of infected animals was reduced to nearly undetectable levels by oral administration of HDP-CDV, but not by intravenous administration of comparable amounts of cidofovir.

In additional research presented at the conference, HDP-CDV was found by Kern to be active in lab tissue cultures against infections caused by cytomegalovirus, herpes virus, varicella zoster virus, and Epstein Barr virus, raising the possibility that the compound might be useful for a variety of more common viral infections. Smallpox continues to be a top concern, however.

"Until now, the eradication and control of smallpox relied upon vaccination," Hostetler said. "The results from the VASDHS/UCSD, USAMRIID, CDC and the University of Alabama suggest that antiviral drugs given orally in a regimen consisting of as few as 5 doses might be used as an alternative to treat and contain a future outbreak of smallpox, especially in those individuals who cannot safely be vaccinated."

Over the years, smallpox has killed millions of people. Caused by variola virus, the disease is spread from one person to another by direct contact or by infected saliva droplets carried through the air when someone coughs. Although the majority of smallpox patients recover, death occurs in up to 30 percent of cases, according to the World Health Organization.

Routine vaccination against smallpox ended in 1972 and many considered smallpox infection eliminated from the world in 1977. However, the level of immunity, if any, among persons who were vaccinated before 1972 is uncertain, the CDC says. Therefore, these persons are assumed to be susceptible.

Although the United States has an emergency supply of smallpox vaccine, the CDC says vaccination against smallpox is associated with some risk for adverse reactions, such as brain inflammation, and vaccination is not currently recommended until after a smallpox outbreak has been identified, when a mass vaccination campaign utilizing the national stockpile would occur.

Hostetler’s research was supported by grants from the Department of Defense, the NIAID, the National Eye Institute, and the Veterans Affairs San Diego Healthcare System.

UCSD is handling the licensing for a joint VASDHS/UCSD invention covering a family of compounds that includes HDP-CDV.


Story Source:

The above story is based on materials provided by Department Of Veterans Affairs. Note: Materials may be edited for content and length.


Cite This Page:

Department Of Veterans Affairs. "Researchers Develop First Oral Drug To Treat Smallpox Infection." ScienceDaily. ScienceDaily, 20 March 2002. <www.sciencedaily.com/releases/2002/03/020320081440.htm>.
Department Of Veterans Affairs. (2002, March 20). Researchers Develop First Oral Drug To Treat Smallpox Infection. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2002/03/020320081440.htm
Department Of Veterans Affairs. "Researchers Develop First Oral Drug To Treat Smallpox Infection." ScienceDaily. www.sciencedaily.com/releases/2002/03/020320081440.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Idaho Boy Helps Brother With Disabilities Complete Triathlon

Newsy (July 23, 2014) An 8-year-old boy helped his younger brother, who has a rare genetic condition that's confined him to a wheelchair, finish a triathlon. Video provided by Newsy
Powered by NewsLook.com
Stone Fruit Listeria Scare Causes Sweeping Recall

Stone Fruit Listeria Scare Causes Sweeping Recall

Newsy (July 22, 2014) The Wawona Packing Company has issued a voluntary recall on the stone fruit it distributes due to a possible Listeria outbreak. Video provided by Newsy
Powered by NewsLook.com
Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Newsy (July 22, 2014) The 83 new genetic markers could open dozens of new avenues for schizophrenia treatment research. Video provided by Newsy
Powered by NewsLook.com
CDC Head Concerned About a Post-Antibiotic Era

CDC Head Concerned About a Post-Antibiotic Era

AP (July 22, 2014) Sounding alarms about the growing threat of antibiotic resistance, CDC Director Tom Frieden warned Tuesday if the global community does not confront the problem soon, the world will be living in a devastating post-antibiotic era. (July 22) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins